Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
Text Size

Health News

Anti-Delirium Drug May Harm Critically Ill Patients

Anti-Delirium Drug May Harm Critically Ill Patients


THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates.

When given to critically ill patients, it may even be linked to a more severe type of delirium, a longer intensive care stay and increased mortality, the new study suggests.

The findings could influence treatment protocols for the most severely ill Alzheimer's and Parkinson's disease patients for whom Exelon is a standard treatment.

In a news release, the Dutch team, led by Dr. Maarten M J van Eijk and Dr. Arjen J.C. Slooter of the University Medical Centre in Utrecht, concludes that "since (the) findings of our study show that rivastigmine does not decrease duration of delirium and might increase mortality in critically ill patients, we do not recommend treatment of delirium with rivastigmine for patients in intensive care."

The authors present their analysis in the Nov. 5 online edition of The Lancet.

Exelon is used to treat delirium among Alzheimer's and Parkinson's patients at various stages of disease and overall health.

In particular, Exelon, which belongs to a class of drugs called cholinesterase inhibitors, is a common treatment for patients hospitalized in intensive care units, where the frequency of delirium runs as high as 80 percent, the authors note.

Their findings stem from work with a little more than 100 Dutch patients, aged 18 and up, who were being cared for in intensive care units and were diagnosed with delirium.

Patients were given either twice daily doses of Exelon (at between 1.5 mg and 6 mg a dose) or a sugar pill, in addition to routine care.

The authors found that the average length of delirium was three days among those not taking Exelon and five days among those getting the drug. In addition, the rate of death among the Exelon group was higher than in the non-Exelon group, although the difference was not deemed statistically significant.

The findings nevertheless raised sufficient concern that the research team halted the investigation mid-stream, before inclusion of another 350 or so patients slated for study participation.

Greg M. Cole, a neuroscientist with the Greater Los Angeles VA Healthcare System and associate director of the Alzheimer's Disease Research Center at the University of California, Los Angeles, David Geffen School of Medicine, said the finding raises a host of questions.

"There may be a lot of factors that could be affecting drug performance here," he noted. "You would want to know what it is specifically about these critically ill people that poses a problem. It is perhaps exposure to anesthesia while hospitalized, or is it a question of acute spiking infections or inflammation among a particularly frail and elderly group? The circumstances need to be carefully defined before we can be really sure what's at issue.

"But I would say that the study also has relevance to an audience that is even broader than just those who might be treated by this particular drug," Cole added. "Because the message here is that even for drugs that are widely used, it isn't usually one size fits all."

Even if a larger pool of people can be treated successfully with this medication, it's important to know if it won't work with a particular population, especially a group such as Alzheimer's patients, he said.

More information

For more on Exelon(rivastigmine), visit the U.S. National Institutes of Health.

Copyright © 2010 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.


Latest News

Crouse Hospital Appoints Chief Information Officer
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

CrouseSports Express After-Hours Ortho Care

Immediate care of orthopedic injuries in kids and adults.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >